# Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

> **NCT01953120** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 20 (actual)

## Conditions studied

- Renal Transplant Rejection

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT01953120
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2021-04
- **Final completion:** 2021-04-21
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953120, "Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01953120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*